Join
Live feed
·
PRReleasevia Quantisnow
OS Therapies Incorporated logo

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

ByQuantisnow·Wall Street's wire, on your screen.
OSTX· OS Therapies Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OSTX (OS Therapies Incorporated) and more on Quantisnow.